Posaconazole: A New Agent for the Prevention and Management of Severe, Refractory or Invasive Fungal Infections. Issue 4 (2008)

• Record Type: Journal Article
• Authors: Page, Andrea V; Liles, W Conrad
• Is Part Of: Canadian journal of infectious diseases & medical microbiology =. Volume 19:Issue 4(2008)
• Page Start: 297
• Page End: 305
• Publication Date: 2008
• Subjects: Aspergillosis -- Candidiasis -- Mucormycosis -- Posaconazole -- Zygomycosis; Communicable diseases -- Periodicals; Infection -- Periodicals; Communicable diseases; Infection; Communicable Diseases; Communicable Disease Control; Electronic journals; Periodicals; Fulltext; Internet Resources; Periodicals; 616.9
• DOI: 10.1155/2008/825901
• Languages: English
• ISSNs: 1712-9532

Abstract

Abstract : Posaconazole is the newest antifungal agent to be approved for use in Canada. With excellent in vitro activity against a broad spectrum of yeasts and filamentous fungi, as well as having a well-tolerated oral formulation, posaconazole offers many potential advantages. Of particular interest are its seemingly lower potential for cross-resistance with other azoles and its activity (unique among oral antifungal agents) against the zygomycetes. As the incidence of both common and uncommon fungal infections increases commensurate with the growing population of immunocompromised individuals, posaconazole may ultimately become an important therapeutic option. The present article reviews the in vitro and in vivo data describing its activity, and focuses on both the proven and the potential clinical applications of this new triazole agent.